



**(301) 366-4960**

**(Issuer Telephone number)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On June 26, 2015, Neuralstem, Inc. (the “Company”) announced that a poster entitled “Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer’s Disease” was presented at the International Society for Stem Cell Research Annual Meeting in Stockholm, Sweden. A copy of the press release and poster are attached to this report as Exhibits 99.01 and 99.02, respectively.

**Item 9.01 Financial Statement and Exhibits.**

**Exhibit No. Description**

99.01	Press Release Dated June 26, 2015.
99.02	Poster presented at Meeting.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 26, 2015 Neuralstem, Inc.

/s/ Richard Garr  
By: Richard Garr  
Chief Executive Officer

**INDEX OF EXHIBITS**

**Exhibit No. Description**

99.01 Press Release Dated June 26, 2015.

99.02 Poster presented at Meeting.